(WSJ) – As bootleg versions of an experimental drug from Eli Lilly flood the market, regulators try to curb supply

Clinics and medspas, promising people transformational weight loss, have figured out how to procure and sell an experimental drug that hasn’t gotten through the government’s drug approval process, prompting serious safety concerns from authorities. 

Social media has amplified interest, with influencers promoting Eli Lilly’s retatrutide—often called “reta”—as a superior weight-loss solution. The black-market compound makes its way to the U.S. through a robust and loosely regulated peptide industry fueled by Chinese suppliers. (Read More)